SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes (SMARTEST)

NCT03982381 PHASE4 COMPLETED

A real-world, nationwide, register-based, randomised trial (RRCT) comparing SGLT2 inhibitors with metformin as standard treatment in early typ 2 diabetes. An open-label trial addressing efficacy with respect to clinically important macro- and microvascular events.

Details

Lead sponsor	Uppsala University
Phase	PHASE4
Status	COMPLETED
Enrolment	2067
Start date	Thu Sep 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Jan 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Type 2 Diabetes

Interventions

• Metformin
• Dapagliflozin 10 MG

Countries

Sweden